BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 22544263)

  • 21. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    Chiu YM; Lai MS; Chan KA
    PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients.
    Schwaneck EC; Krone M; Kreissl-Kemmer S; Weißbrich B; Weiss J; Tony HP; Gadeholt O; Schmalzing M; Geier A
    Clin Rheumatol; 2018 Nov; 37(11):2963-2970. PubMed ID: 30238380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
    Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
    Rodríguez-Tajes S; Miralpeix A; Costa J; López-Suñé E; Laguno M; Pocurull A; Lens S; Mariño Z; Forns X
    J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
    Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
    Wang ST; Tseng CW; Hsu CW; Tung CH; Huang KY; Lu MC; Lai NS
    Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
    Kuo MH; Tseng CW; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
    Dig Dis Sci; 2021 Nov; 66(11):4026-4034. PubMed ID: 33387124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
    Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
    Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
    Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
    World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Spaan M; Bruce M; Agarwal K; Carey I
    Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
    Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
    J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.
    Mo YQ; Liang AQ; Ma JD; Chen LF; Zheng DH; Schumacher HR; Dai L
    BMC Musculoskelet Disord; 2014 Dec; 15():449. PubMed ID: 25532827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country.
    Murt A; Elverdi T; Eskazan AE; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Soysal T
    Ann Hematol; 2020 Nov; 99(11):2671-2677. PubMed ID: 32737632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.